| Zhang, Xinjun |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
| Wang, Lina |
NCT03784222: Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients |
|
|
| Terminated | 4 | 102 | RoW | Blonanserin, MRI and serum BDNF | Sumitomo Pharma (Suzhou) Co., Ltd. | First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin | 11/22 | 11/22 | | |
NCT04825860: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase |
|
|
| Terminated | 2/3 | 83 | Japan, RoW | SEP-363856 50 mg, SEP-363856 75 mg, Placebo | Sumitomo Pharma Co., Ltd. | Schizophrenia | 10/23 | 10/23 | | |
NCT06259526: A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression |
|
|
| Recruiting | 2 | 260 | RoW | Placebo group, JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 low-dose group, JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules, JS1-1-01 pills; JS1-1-01 placebo pills, JS1-1-01 high-dose group, JS1-1-01 pills; Duloxetine hydrochloride placebo capsules, Active drug group, JS1-1-01 placebo pills; Duloxetine hydrochloride enteric coated capsule | Tasly Pharmaceutical Group Co., Ltd | Depression | 04/25 | 04/25 | | |
| Zhao, Yiqing |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06306872: A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules |
|
|
| Recruiting | 1 | 73 | RoW | Sequence A ABSK-011, Sequence B ABSK-011 | Abbisko Therapeutics Co, Ltd | Healthy Subjects | 12/24 | 12/24 | | |
| Sun, Jingjing |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| Sun, Ling |
| No trials found |
